

type of report	Current report
number	52/2013
company	PHARMENA

Successful conclusion of analytical research over the pilot batch of 1-MNA dietary supplement

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and communication on the production of 1-MNA dietary supplement (published in current report no. 36/2013 of 4th June 2013), the Management Board of Pharmena S.A. informs that on 19th July 2013, analytical research over the pilot batch of the product was concluded. The research demonstrated that the process of formulation and production of 1-MNA capsules was performed in a proper manner. The capsules conform to the specification and contain the assumed quantity of active substance 1-MNA.

The 1-MNA dietary supplement is an innovative product that has a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

Having successfully finalised the registration processes of 1-MNA dietary supplement as new foodstuff within the European procedure, the Issuer will commence the manufacture of 1-MNA dietary supplement and place the product on EU markets.

The information is made public due to the fact that introduction of innovative dietary supplement containing 1-MNA on the market may have a significant influence on the Company's revenue in the next few years.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1)".

Representatives of the company:

- Konrad Palka – President of the Board
- Marzena Wieczorkowska – Vice President of the Board